Related Experiment Video
Updated: Jun 9, 2026
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Development and validation of a pediatric severity index for sickle cell patients
Xandra W van den Tweel1, Johanna H van der Lee, Harriët Heijboer
1Department of Pediatric Hematology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands. x.w.vandentweel@amc.nl
Insights
Researchers developed and validated a new pediatric severity index for sickle cell disease (SCD). This tool accurately measures disease severity in children, aiding in better patient classification and management.
Area of Science:
- Pediatrics
- Hematology
- Clinical Research
Background:
- Sickle cell disease (SCD) lacks a universally accepted severity measurement tool for pediatric patients.
- Accurate severity assessment is crucial for effective management and prognosis in children with SCD.
Purpose of the Study:
- To develop and validate a novel severity index for pediatric sickle cell disease.
- To establish a reliable instrument for classifying SCD severity in children.
Main Methods:
- A 12-item index was developed and validated using data from 92 pediatric SCD patients.
- Validity was assessed by comparing index scores with subjective and objective severity classifications, genotype, alpha-gene deletions, hospitalization rates, age, and risk of death scores.
- Three different weighting systems were explored.
Main Results:
- The developed index demonstrated significant differences in scores across mild, moderate, and severe SCD classifications (P < 0.01).
- The index effectively differentiated patients based on genotype and alpha-gene deletions (P < 0.01).
- Moderate correlation was observed with hospitalization rates; weak associations were found with age and risk of death scores.
Conclusions:
- This study presents the first pediatric SCD severity index developed and validated using modern clinimetric methods.
- The index shows promise for accurate severity assessment in children with SCD.
- Further validation in larger, prospective cohorts, ideally including newborns diagnosed at birth, is recommended.
Abstract:
There is no instrument to measure severity of sickle cell disease (SCD) in pediatric patients that is generally accepted. The aim of this study was to develop and validate a severity index for SCD in children. We developed an index consisting of 12 items and tested its validity of the index using data from 92 children. We tested whether different scores were obtained for patients classified by severity both subjectively and objectively by a partially validated existing index. Furthermore, we tested whether the index could differentiate patients classified according to genotype or the number of α-gene deletions and evaluated whether the score on the index was correlated with the average number and days of hospitalizations/year, age and a risk of death score. We explored the effect of three different weighting systems (Score A, B, and C) to summarize these items. All weightings demonstrated a significant difference between the scores of mild, moderate, and severely affected patients, as classified by a subjective rating or with an existing index (P < 0.01). The index clearly differentiated patients by genotype (P < 0.01) or α-gene deletions (P < 0.01). The correlation with hospitalization was moderate. Age and the risk of death score were weakly associated with the pediatric severity index for SCD. This is the first pediatric SCD severity index that was developed and validated using modern clinimetric methodology. The validity and reliability of this index should be further evaluated in a prospective study including a larger cohort, preferably diagnosed at birth.